AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IMNM · NASDAQ · Biotechnology

Immunome (IMNM)

Develops targeted oncology drugs across ADCs, radioligands and small molecules.

$24.50

vs last close−1.25 (−4.85%)

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
MarketBeatAug 17Clinical
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
GlobeNewsWireAug 17Clinical
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
Seeking AlphaAug 13
Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM
Defense WorldJul 24
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
Business WireJul 20
What This Immunome Sale Means a Day Before a Big FDA Milestone
The Motley FoolJul 12
Immunome Stock Up 32% in a Month: Here's What You Should Know
Zacks Investment ResearchJul 10
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Business WireJul 8
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireJul 7
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
GuruFocusJun 11
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Business WireJun 11
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking AlphaJun 9
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
Seeking AlphaJun 9
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireJun 4
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
GuruFocusMay 30
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Business WireMay 30
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
GuruFocusMay 27
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Business WireMay 27
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Business WireMay 12
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireMay 5
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Business WireApr 29
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Business WireApr 21
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
FXEmpireApr 14
Max Rosett Sells 65,000 Shares of Immunome (NASDAQ:IMNM) Stock
Defense WorldApr 5